Interpharm Holdings Inc - Current report filing (8-K)
21 Décembre 2007 - 7:22PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date
of
Report (Date of earliest event reported)
December
21, 2007
Interpharm
Holdings, Inc.
(Exact
name of Registrant as specified in charter)
Delaware
|
0-22710
|
13-3673965
|
(State
or other jurisdiction of incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
75
Adams Avenue, Hauppauge, New York
|
11788
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant's
telephone number, including area code:
(631)
952 0214
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))
o
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
8.01
Other
Events
As
Interpharm Holdings, Inc. (“Holdings”) previously disclosed, on October 15,
2007, it received notice from the American Stock Exchange (“AMEX”) of a
continuing listing deficiency due to the fact that it did not file its Annual
Report on Form 10-K as required by Sections 134 and 1101 of the AMEX Company
Guide. Trading in Holding’s stock was halted pending Holdings curing the
deficiency.
As
of the
date of this Current Report, Holdings has been advised by the AMEX that its
continuing listing deficiency has been resolved as a result of Holdings filing
its Annual Report on Form 10-K and its Form 10-Q for the quarter ended September
30, 2007. Holding’s common stock re-commenced trading on December 20,
2007.
Signatures
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
INTERPHARM
HOLDINGS, INC.
|
|
|
December
21, 2007
|
By:
/s/ Peter
Giallorenzo
|
|
Peter Giallorenzo
|
|
Chief Financial Officer and Chief Operating
Officer
|
Interpharm (AMEX:IPA)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
Interpharm (AMEX:IPA)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025
Real-Time news about Interpharm Holdings, Inc. (American Stock Exchange): 0 recent articles
Plus d'articles sur Interpharm Holdings Inc